Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma
- 1 October 1990
- journal article
- research article
- Published by Wiley in European Journal of Biochemistry
- Vol. 193 (2) , 485-493
- https://doi.org/10.1111/j.1432-1033.1990.tb19363.x
Abstract
There is evidence that by catalyzing thrombin inhibition, several glycosaminoglycans can inhibit the thrombin-mediated amplification reactions of coagulation and thereby delay prothrombin activation. The two amplification reactions can apparently be catalysed by endogenously generated factor Xa and thrombin. This study provides evidence which suggests that on a molar basis, an agent which can only catalyse thrombin inhibition is approximately 10 times more effective than an agent which can only catalyse factor Xa inhibition in their ability to inhibit intrinsic prothrombin activation. We determined the concentrations of each of heparin, dermatan sulfate and a pentasaccharide with high affinity for antithrombin III, to delay intrinsic prothrombin activation for at least 15s. Heparin catalyses both thrombin and factor Xa inhibition; dermatan sulfate catalyses only thrombin inhibition, while the pentasaccharide only catalyses factor Xa inhibition. Efficient prothrombin activation, which coincided with both factor X activation and factor V proteolysis, was first observed 45s after CaC12 was added to contactactivated plasma. Heparin (.apprxeq. 0.1 .mu.M) prolonged by at least 30 s the time required for the activation of the three clotting factors to begin. The minimum concentrations of the pentasaccharide and dermatan sulfate to delay the activation of prothrombin, factors X and V were .apprxeq. 50 .mu.M and .apprxeq. 5 .mu.M, respectively. Thus, each anticoagulant could inhibit intrinsic prothrombin activation only when it inhibited activation of both factors X and V. A combination of .apprxeq. 5 .mu.M pentasaccharide and .apprxeq. 0.05 .mu.M dermatan sulfate similarly delayed the activation of all three clotting factors. Thus, while catalysis of thrombin inhibition is a more effective pathway than catalysis of factor Xa inhibition for delaying prothrombin activation, the simultaneous catalysis of thrombin and factor Xa inhibition can synergistically improve the ability of a sulfated polysaccharide to delay prothrombin activation.This publication has 38 references indexed in Scilit:
- Activation of human factor V by factor Xa and thrombinBiochemistry, 1990
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan SulfateaAnnals of the New York Academy of Sciences, 1989
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphateBritish Journal of Haematology, 1985
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factorBritish Journal of Haematology, 1984
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fractionThrombosis Research, 1982
- Role of human factor VIII in factor X activation.Journal of Clinical Investigation, 1982
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparinThrombosis Research, 1981
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- The activation of factor V by factor Xa or α-chymotrypsin and comparison with thrombin and RVV-V action. An improved factor V isolation procedureBiochemistry, 1976